CRBP vs. KURA, CRGX, HUMA, PHVS, KROS, ANNX, RAPP, MREO, ORKA, and TRDA
Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Kura Oncology (KURA), CARGO Therapeutics (CRGX), Humacyte (HUMA), Pharvaris (PHVS), Keros Therapeutics (KROS), Annexon (ANNX), Rapport Therapeutics (RAPP), Mereo BioPharma Group (MREO), Oruka Therapeutics (ORKA), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical products" industry.
Corbus Pharmaceuticals vs.
Corbus Pharmaceuticals (NASDAQ:CRBP) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.
Kura Oncology is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Corbus Pharmaceuticals presently has a consensus price target of $62.00, indicating a potential upside of 420.13%. Kura Oncology has a consensus price target of $27.38, indicating a potential upside of 277.07%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Kura Oncology.
In the previous week, Corbus Pharmaceuticals had 1 more articles in the media than Kura Oncology. MarketBeat recorded 4 mentions for Corbus Pharmaceuticals and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.00 beat Corbus Pharmaceuticals' score of 0.67 indicating that Kura Oncology is being referred to more favorably in the news media.
Corbus Pharmaceuticals has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 4.0% of Corbus Pharmaceuticals shares are held by insiders. Comparatively, 5.5% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Corbus Pharmaceuticals received 24 more outperform votes than Kura Oncology when rated by MarketBeat users. However, 69.44% of users gave Kura Oncology an outperform vote while only 66.82% of users gave Corbus Pharmaceuticals an outperform vote.
Corbus Pharmaceuticals' return on equity of -42.28% beat Kura Oncology's return on equity.
Summary
Corbus Pharmaceuticals beats Kura Oncology on 10 of the 14 factors compared between the two stocks.
Get Corbus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corbus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRBP) was last updated on 1/21/2025 by MarketBeat.com Staff
